Cypher Sales In Japan Help Cordis Achieve 19% Revenue Jump In 2004

Johnson & Johnson's Cordis unit grew its top line 19% to $3.21 bil. in 2004, due in part to robust Cypher sirolimus-eluting stent sales in Japan, CEO William Weldon stated in a Jan. 25 earnings call